#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-12	Evolutionary	_
1-2	13-26	modifications	_
1-3	27-29	in	_
1-4	30-35	human	_
1-5	36-41	brain	_
1-6	42-54	connectivity	_
1-7	55-65	associated	_
1-8	66-70	with	_
1-9	71-84	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	85-88	See	_
1-11	89-95	Vértes	_
1-12	96-99	and	_
1-13	100-108	Seidlitz	_
1-14	109-110	(	_
1-15	111-114	doi	_
1-16	115-116	:	_
1-17	117-118	)	_
1-18	119-122	for	_
1-19	123-124	a	_
1-20	125-135	scientific	_
1-21	136-146	commentary	_
1-22	147-149	on	_
1-23	150-154	this	_
1-24	155-162	article	_
1-25	163-164	.	_

2-1	165-167	Is	_
2-2	168-181	schizophrenia	_
2-3	182-183	a	_
2-4	184-194	by-product	_
2-5	195-197	of	_
2-6	198-203	human	_
2-7	204-209	brain	_
2-8	210-219	evolution	_
2-9	220-221	?	_

3-1	222-224	By	_
3-2	225-234	comparing	_
3-3	235-238	the	_
3-4	239-244	human	_
3-5	245-248	and	_
3-6	249-259	chimpanzee	_
3-7	260-271	connectomes	_
3-8	272-273	,	_
3-9	274-277	van	_
3-10	278-281	den	_
3-11	282-288	Heuvel	_
3-12	289-291	et	_
3-13	292-294	al	_
3-14	295-296	.	_

4-1	297-308	demonstrate	_
4-2	309-313	that	_
4-3	314-325	connections	_
4-4	326-332	unique	_
4-5	333-335	to	_
4-6	336-339	the	_
4-7	340-345	human	_
4-8	346-351	brain	_
4-9	352-356	show	_
4-10	357-364	greater	_
4-11	365-376	involvement	_
4-12	377-379	in	_
4-13	380-393	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-14	394-403	pathology	_
4-15	404-405	.	_

5-1	406-419	Modifications	_
5-2	420-422	in	_
5-3	423-430	service	_
5-4	431-433	of	_
5-5	434-446	higher-order	_
5-6	447-452	brain	_
5-7	453-462	functions	_
5-8	463-466	may	_
5-9	467-471	have	_
5-10	472-480	rendered	_
5-11	481-484	the	_
5-12	485-490	brain	_
5-13	491-495	more	_
5-14	496-506	vulnerable	_
5-15	507-509	to	_
5-16	510-521	dysfunction	_
5-17	522-523	.	_

6-1	524-532	Abstract	_
6-2	533-536	The	_
6-3	537-544	genetic	_
6-4	545-550	basis	_
6-5	551-554	and	_
6-6	555-569	human-specific	_
6-7	570-579	character	_
6-8	580-582	of	_
6-9	583-596	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-10	597-600	has	_
6-11	601-604	led	_
6-12	605-607	to	_
6-13	608-611	the	_
6-14	612-622	hypothesis	_
6-15	623-627	that	_
6-16	628-633	human	_
6-17	634-639	brain	_
6-18	640-649	evolution	_
6-19	650-653	may	_
6-20	654-658	have	_
6-21	659-665	played	_
6-22	666-667	a	_
6-23	668-672	role	_
6-24	673-675	in	_
6-25	676-679	the	_
6-26	680-691	development	_
6-27	692-694	of	_
6-28	695-698	the	_
6-29	699-707	disorder	_
6-30	708-709	.	_

7-1	710-712	We	_
7-2	713-721	examined	_
7-3	722-743	schizophrenia-related	_
7-4	744-751	changes	_
7-5	752-754	in	_
7-6	755-760	brain	_
7-7	761-773	connectivity	_
7-8	774-776	in	_
7-9	777-780	the	_
7-10	781-788	context	_
7-11	789-791	of	_
7-12	792-804	evolutionary	_
7-13	805-812	changes	_
7-14	813-815	in	_
7-15	816-821	human	_
7-16	822-827	brain	_
7-17	828-834	wiring	_
7-18	835-837	by	_
7-19	838-847	comparing	_
7-20	848-850	in	_
7-21	851-855	vivo	_
7-22	856-868	neuroimaging	_
7-23	869-873	data	_
7-24	874-878	from	_
7-25	879-885	humans	_
7-26	886-889	and	_
7-27	890-901	chimpanzees	_
7-28	902-903	,	_
7-29	904-907	one	_
7-30	908-910	of	_
7-31	911-914	our	_
7-32	915-922	closest	_
7-33	923-929	living	_
7-34	930-942	evolutionary	_
7-35	943-952	relatives	_
7-36	953-956	and	_
7-37	957-958	a	_
7-38	959-966	species	_
7-39	967-971	with	_
7-40	972-977	which	_
7-41	978-980	we	_
7-42	981-986	share	_
7-43	987-988	a	_
7-44	989-993	very	_
7-45	994-1000	recent	_
7-46	1001-1007	common	_
7-47	1008-1016	ancestor	_
7-48	1017-1018	.	_

8-1	1019-1021	We	_
8-2	1022-1032	contrasted	_
8-3	1033-1036	the	_
8-4	1037-1047	connectome	_
8-5	1048-1054	layout	_
8-6	1055-1062	between	_
8-7	1063-1066	the	_
8-8	1067-1077	chimpanzee	_
8-9	1078-1081	and	_
8-10	1082-1087	human	_
8-11	1088-1093	brain	_
8-12	1094-1097	and	_
8-13	1098-1106	compared	_
8-14	1107-1118	differences	_
8-15	1119-1123	with	_
8-16	1124-1127	the	_
8-17	1128-1135	pattern	_
8-18	1136-1138	of	_
8-19	1139-1160	schizophrenia-related	_
8-20	1161-1168	changes	_
8-21	1169-1171	in	_
8-22	1172-1177	brain	_
8-23	1178-1190	connectivity	_
8-24	1191-1193	as	_
8-25	1194-1202	observed	_
8-26	1203-1205	in	_
8-27	1206-1214	patients	_
8-28	1215-1216	.	_

9-1	1217-1219	We	_
9-2	1220-1224	show	_
9-3	1225-1233	evidence	_
9-4	1234-1236	of	_
9-5	1237-1249	evolutionary	_
9-6	1250-1263	modifications	_
9-7	1264-1266	of	_
9-8	1267-1272	human	_
9-9	1273-1278	brain	_
9-10	1279-1291	connectivity	_
9-11	1292-1294	to	_
9-12	1295-1308	significantly	_
9-13	1309-1316	overlap	_
9-14	1317-1321	with	_
9-15	1322-1325	the	_
9-16	1326-1334	cortical	_
9-17	1335-1342	pattern	_
9-18	1343-1345	of	_
9-19	1346-1367	schizophrenia-related	_
9-20	1368-1383	dysconnectivity	_
9-21	1384-1385	(	_
9-22	1386-1387	P	_
9-23	1388-1389	<	_
9-24	1390-1395	0.001	_
9-25	1396-1397	,	_
9-26	1398-1409	permutation	_
9-27	1410-1417	testing	_
9-28	1418-1419	)	_
9-29	1420-1421	.	_

10-1	1422-1424	We	_
10-2	1425-1434	validated	_
10-3	1435-1440	these	_
10-4	1441-1448	effects	_
10-5	1449-1451	in	_
10-6	1452-1457	three	_
10-7	1458-1468	additional	_
10-8	1469-1470	,	_
10-9	1471-1482	independent	_
10-10	1483-1496	schizophrenia	_
10-11	1497-1505	datasets	_
10-12	1506-1507	.	_

11-1	1508-1510	We	_
11-2	1511-1518	further	_
11-3	1519-1527	assessed	_
11-4	1528-1531	the	_
11-5	1532-1543	specificity	_
11-6	1544-1546	of	_
11-7	1547-1554	effects	_
11-8	1555-1557	by	_
11-9	1558-1567	examining	_
11-10	1568-1573	brain	_
11-11	1574-1589	dysconnectivity	_
11-12	1590-1598	patterns	_
11-13	1599-1601	in	_
11-14	1602-1607	seven	_
11-15	1608-1613	other	_
11-16	1614-1625	psychiatric	_
11-17	1626-1629	and	_
11-18	1630-1642	neurological	_
11-19	1643-1648	brain	_
11-20	1649-1658	disorders	_
11-21	1659-1660	(	_
11-22	1661-1670	including	_
11-23	1671-1672	,	_
11-24	1673-1678	among	_
11-25	1679-1685	others	_
11-26	1686-1687	,	_
11-27	1688-1693	major	_
11-28	1694-1704	depressive	_
11-29	1705-1713	disorder	_
11-30	1714-1717	and	_
11-31	1718-1738	obsessive-compulsive	_
11-32	1739-1747	disorder	_
11-33	1748-1749	,	_
11-34	1750-1758	arguably	_
11-35	1759-1772	characterized	_
11-36	1773-1775	by	_
11-37	1776-1787	behavioural	_
11-38	1788-1796	symptoms	_
11-39	1797-1801	that	_
11-40	1802-1805	are	_
11-41	1806-1810	less	_
11-42	1811-1819	specific	_
11-43	1820-1822	to	_
11-44	1823-1829	humans	_
11-45	1830-1831	)	_
11-46	1832-1833	,	_
11-47	1834-1839	which	_
11-48	1840-1846	showed	_
11-49	1847-1849	no	_
11-50	1850-1854	such	_
11-51	1855-1867	associations	_
11-52	1868-1872	with	_
11-53	1873-1886	modifications	_
11-54	1887-1889	of	_
11-55	1890-1895	human	_
11-56	1896-1901	brain	_
11-57	1902-1914	connectivity	_
11-58	1915-1916	.	_

12-1	1917-1928	Comparisons	_
12-2	1929-1931	of	_
12-3	1932-1937	brain	_
12-4	1938-1950	connectivity	_
12-5	1951-1957	across	_
12-6	1958-1964	humans	_
12-7	1965-1966	,	_
12-8	1967-1977	chimpanzee	_
12-9	1978-1981	and	_
12-10	1982-1990	macaques	_
12-11	1991-1998	further	_
12-12	1999-2006	suggest	_
12-13	2007-2011	that	_
12-14	2012-2020	features	_
12-15	2021-2023	of	_
12-16	2024-2036	connectivity	_
12-17	2037-2041	that	_
12-18	2042-2049	evolved	_
12-19	2050-2052	in	_
12-20	2053-2056	the	_
12-21	2057-2062	human	_
12-22	2063-2070	lineage	_
12-23	2071-2077	showed	_
12-24	2078-2081	the	_
12-25	2082-2091	strongest	_
12-26	2092-2103	association	_
12-27	2104-2106	to	_
12-28	2107-2110	the	_
12-29	2111-2119	disorder	_
12-30	2120-2121	,	_
12-31	2122-2126	that	_
12-32	2127-2129	is	_
12-33	2130-2131	,	_
12-34	2132-2137	brain	_
12-35	2138-2146	circuits	_
12-36	2147-2158	potentially	_
12-37	2159-2166	related	_
12-38	2167-2169	to	_
12-39	2170-2175	human	_
12-40	2176-2188	evolutionary	_
12-41	2189-2204	specializations	_
12-42	2205-2206	.	_

13-1	2207-2212	Taken	_
13-2	2213-2221	together	_
13-3	2222-2223	,	_
13-4	2224-2227	our	_
13-5	2228-2236	findings	_
13-6	2237-2244	suggest	_
13-7	2245-2249	that	_
13-8	2250-2264	human-specific	_
13-9	2265-2273	features	_
13-10	2274-2276	of	_
13-11	2277-2287	connectome	_
13-12	2288-2300	organization	_
13-13	2301-2304	may	_
13-14	2305-2307	be	_
13-15	2308-2316	enriched	_
13-16	2317-2320	for	_
13-17	2321-2328	changes	_
13-18	2329-2331	in	_
13-19	2332-2337	brain	_
13-20	2338-2350	connectivity	_
13-21	2351-2358	related	_
13-22	2359-2361	to	_
13-23	2362-2375	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-24	2376-2377	.	_

14-1	2378-2391	Modifications	_
14-2	2392-2394	in	_
14-3	2395-2400	human	_
14-4	2401-2406	brain	_
14-5	2407-2419	connectivity	_
14-6	2420-2422	in	_
14-7	2423-2430	service	_
14-8	2431-2433	of	_
14-9	2434-2440	higher	_
14-10	2441-2446	order	_
14-11	2447-2452	brain	_
14-12	2453-2462	functions	_
14-13	2463-2466	may	_
14-14	2467-2471	have	_
14-15	2472-2483	potentially	_
14-16	2484-2488	also	_
14-17	2489-2497	rendered	_
14-18	2498-2501	the	_
14-19	2502-2507	brain	_
14-20	2508-2518	vulnerable	_
14-21	2519-2521	to	_
14-22	2522-2527	brain	_
14-23	2528-2539	dysfunction	_
14-24	2540-2541	.	_

15-1	2542-2551	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-2	2552-2555	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-3	2556-2563	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-4	2564-2572	Subjects	_
15-5	2573-2576	and	_
15-6	2577-2581	data	_
15-7	2582-2593	acquisition	_
15-8	2594-2603	Principal	_
15-9	2604-2617	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-10	2618-2625	dataset	_
15-11	2626-2629	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-12	2630-2634	data	_
15-13	2635-2637	of	_
15-14	2638-2641	the	_
15-15	2642-2651	principal	_
15-16	2652-2665	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-17	2666-2673	dataset	_
15-18	2674-2682	included	_
15-19	2683-2686	the	_
15-20	2687-2698	examination	_
15-21	2699-2701	of	_
15-22	2702-2703	3	_
15-23	2704-2705	T	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-24	2706-2708	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-25	2709-2712	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-26	2713-2731	diffusion-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
15-27	2732-2739	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
15-28	2740-2741	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
15-29	2742-2745	DWI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
15-30	2746-2747	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
15-31	2748-2752	data	_
15-32	2753-2755	of	_
15-33	2756-2758	48	_
15-34	2759-2767	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-35	2768-2772	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-36	2773-2786	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-37	2787-2790	and	_
15-38	2791-2793	43	_
15-39	2794-2798	age-	_
15-40	2799-2802	and	_
15-41	2803-2817	gender-matched	_
15-42	2818-2825	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-43	2826-2833	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-44	2834-2842	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-45	2843-2844	(	_
15-46	2845-2857	demographics	_
15-47	2858-2864	listed	_
15-48	2865-2867	in	_
15-49	2868-2881	Supplementary	_
15-50	2882-2887	Table	_
15-51	2888-2889	2	_
15-52	2890-2893	and	_
15-53	2894-2895	)	_
15-54	2896-2897	.	_

16-1	2898-2901	All	_
16-2	2902-2914	participants	_
16-3	2915-2923	provided	_
16-4	2924-2932	informed	_
16-5	2933-2940	consent	_
16-6	2941-2943	as	_
16-7	2944-2952	approved	_
16-8	2953-2955	by	_
16-9	2956-2959	the	_
16-10	2960-2965	local	_
16-11	2966-2973	medical	_
16-12	2974-2980	ethics	_
16-13	2981-2990	committee	_
16-14	2991-2994	for	_
16-15	2995-3003	research	_
16-16	3004-3006	in	_
16-17	3007-3013	humans	_
16-18	3014-3015	(	_
16-19	3016-3020	METC	_
16-20	3021-3022	)	_
16-21	3023-3024	,	_
16-22	3025-3029	with	_
16-23	3030-3040	procedures	_
16-24	3041-3048	carried	_
16-25	3049-3052	out	_
16-26	3053-3062	according	_
16-27	3063-3065	to	_
16-28	3066-3069	the	_
16-29	3070-3080	directives	_
16-30	3081-3083	of	_
16-31	3084-3087	the	_
16-32	3088-3099	Declaration	_
16-33	3100-3102	of	_
16-34	3103-3111	Helsinki	_
16-35	3112-3113	(	_
16-36	3114-3123	amendment	_
16-37	3124-3126	of	_
16-38	3127-3136	Edinburgh	_
16-39	3137-3138	,	_
16-40	3139-3143	2000	_
16-41	3144-3145	)	_
16-42	3146-3147	.	_

17-1	3148-3151	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-2	3152-3156	data	_
17-3	3157-3161	were	_
17-4	3162-3170	acquired	_
17-5	3171-3173	on	_
17-6	3174-3175	a	_
17-7	3176-3184	clinical	_
17-8	3185-3192	Philips	_
17-9	3193-3196	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-10	3197-3204	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-11	3205-3208	and	_
17-12	3209-3217	included	_
17-13	3218-3221	the	_
17-14	3222-3233	acquisition	_
17-15	3234-3236	of	_
17-16	3237-3238	a	_
17-17	3239-3241	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
17-18	3242-3246	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
17-19	3247-3250	and	_
17-20	3251-3252	a	_
17-21	3253-3256	DWI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImagingProtocol
17-22	3257-3261	scan	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImagingProtocol
17-23	3262-3263	(	_
17-24	3264-3277	Supplementary	_
17-25	3278-3286	material	_
17-26	3287-3288	)	_
17-27	3289-3290	.	_

18-1	3291-3304	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-2	3305-3315	validation	_
18-3	3316-3324	datasets	_
18-4	3325-3332	Effects	_
18-5	3333-3337	were	_
18-6	3338-3347	validated	_
18-7	3348-3350	in	_
18-8	3351-3354	two	_
18-9	3355-3365	additional	_
18-10	3366-3367	,	_
18-11	3368-3379	independent	_
18-12	3380-3393	schizophrenia	_
18-13	3394-3404	validation	_
18-14	3405-3413	datasets	_
18-15	3414-3415	(	_
18-16	3416-3424	datasets	_
18-17	3425-3433	acquired	_
18-18	3434-3436	on	_
18-19	3437-3438	3	_
18-20	3439-3440	T	_
18-21	3441-3448	scanner	_
18-22	3449-3453	with	_
18-23	3454-3457	the	_
18-24	3458-3462	same	_
18-25	3463-3470	imaging	_
18-26	3471-3479	protocol	_
18-27	3480-3482	as	_
18-28	3483-3486	the	_
18-29	3487-3496	principal	_
18-30	3497-3504	dataset	_
18-31	3505-3506	)	_
18-32	3507-3508	,	_
18-33	3509-3518	including	_
18-34	3519-3521	40	_
18-35	3522-3530	patients	_
18-36	3531-3534	and	_
18-37	3535-3537	37	_
18-38	3538-3545	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-39	3546-3554	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-40	3555-3558	and	_
18-41	3559-3561	30	_
18-42	3562-3570	patients	_
18-43	3571-3574	and	_
18-44	3575-3577	33	_
18-45	3578-3585	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-46	3586-3594	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-47	3595-3596	,	_
18-48	3597-3609	respectively	_
18-49	3610-3611	(	_
18-50	3612-3625	Supplementary	_
18-51	3626-3631	Table	_
18-52	3632-3633	3	_
18-53	3634-3635	)	_
18-54	3636-3637	.	_

19-1	3638-3643	Other	_
19-2	3644-3653	disorders	_
19-3	3654-3656	To	_
19-4	3657-3664	examine	_
19-5	3665-3676	specificity	_
19-6	3677-3679	in	_
19-7	3680-3685	brain	_
19-8	3686-3698	connectivity	_
19-9	3699-3706	effects	_
19-10	3707-3709	to	_
19-11	3710-3723	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-12	3724-3725	,	_
19-13	3726-3728	we	_
19-14	3729-3741	additionally	_
19-15	3742-3750	included	_
19-16	3751-3753	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
19-17	3754-3757	and	_
19-18	3758-3761	DWI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImagingProtocol
19-19	3762-3766	data	_
19-20	3767-3769	of	_
19-21	3770-3775	seven	_
19-22	3776-3781	other	_
19-23	3782-3787	brain	_
19-24	3788-3798	conditions	_
19-25	3799-3800	(	_
19-26	3801-3804	all	_
19-27	3805-3807	in	_
19-28	3808-3813	their	_
19-29	3814-3817	own	_
19-30	3818-3821	way	_
19-31	3822-3829	related	_
19-32	3830-3832	to	_
19-33	3833-3840	changes	_
19-34	3841-3843	to	_
19-35	3844-3849	white	_
19-36	3850-3856	matter	_
19-37	3857-3869	connectivity	_
19-38	3870-3871	)	_
19-39	3872-3873	,	_
19-40	3874-3883	including	_
19-41	3884-3889	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
19-42	3890-3900	depressive	_
19-43	3901-3909	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
19-44	3910-3911	(	_
19-45	3912-3915	MDD	_
19-46	3916-3917	,	_
19-47	3918-3934	patients/matched	_
19-48	3935-3943	controls	_
19-49	3944-3945	n	_
19-50	3946-3947	=	_
19-51	3948-3955	211/476	_
19-52	3956-3957	)	_
19-53	3958-3959	,	_
19-54	3960-3980	obsessive-compulsive	_
19-55	3981-3989	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
19-56	3990-3991	(	_
19-57	3992-3995	OCD	_
19-58	3996-3997	,	_
19-59	3998-3999	n	_
19-60	4000-4001	=	_
19-61	4002-4007	36/42	_
19-62	4008-4009	)	_
19-63	4010-4011	,	_
19-64	4012-4019	bipolar	_
19-65	4020-4028	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
19-66	4029-4030	(	_
19-67	4031-4032	n	_
19-68	4033-4034	=	_
19-69	4035-4042	147/477	_
19-70	4043-4044	)	_
19-71	4045-4046	,	_
19-72	4047-4053	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
19-73	4054-4062	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
19-74	4063-4071	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
19-75	4072-4073	(	_
19-76	4074-4077	ASD	_
19-77	4078-4079	,	_
19-78	4080-4081	n	_
19-79	4082-4083	=	_
19-80	4084-4089	73/64	_
19-81	4090-4091	,	_
19-82	4092-4097	ABIDE	_
19-83	4098-4105	dataset	_
19-84	4106-4107	)	_
19-85	4108-4109	,	_
19-86	4110-4121	behavioural	_
19-87	4122-4129	variant	_
19-88	4130-4144	frontotemporal	_
19-89	4145-4153	dementia	_
19-90	4154-4155	(	_
19-91	4156-4161	bvFTD	_
19-92	4162-4163	,	_
19-93	4164-4165	n	_
19-94	4166-4167	=	_
19-95	4168-4173	20/20	_
19-96	4174-4175	)	_
19-97	4176-4177	,	_
19-98	4178-4187	Alzheimer	_
19-99	4188-4189	’	_
19-100	4190-4191	s	_
19-101	4192-4199	disease	_
19-102	4200-4201	(	_
19-103	4202-4203	n	_
19-104	4204-4205	=	_
19-105	4206-4211	20/20	_
19-106	4212-4213	)	_
19-107	4214-4217	and	_
19-108	4218-4222	mild	_
19-109	4223-4232	cognitive	_
19-110	4233-4243	impairment	_
19-111	4244-4245	(	_
19-112	4246-4249	MCI	_
19-113	4250-4251	,	_
19-114	4252-4253	n	_
19-115	4254-4255	=	_
19-116	4256-4261	28/28	_
19-117	4262-4263	)	_
19-118	4264-4265	.	_

20-1	4266-4273	Details	_
20-2	4274-4276	on	_
20-3	4277-4282	these	_
20-4	4283-4291	datasets	_
20-5	4292-4295	are	_
20-6	4296-4304	provided	_
20-7	4305-4307	in	_
20-8	4308-4311	the	_
20-9	4312-4325	Supplementary	_
20-10	4326-4334	material	_
20-11	4335-4338	and	_
20-12	4339-4352	Supplementary	_
20-13	4353-4359	Tables	_
20-14	4360-4361	6	_
20-15	4362-4365	and	_
20-16	4366-4367	7	_
20-17	4368-4371	and	_
20-18	4372-4373	.	_

21-1	4374-4376	To	_
21-2	4377-4385	validate	_
21-3	4386-4390	that	_
21-4	4391-4399	observed	_
21-5	4400-4413	schizophrenia	_
21-6	4414-4421	effects	_
21-7	4422-4426	were	_
21-8	4427-4438	independent	_
21-9	4439-4441	of	_
21-10	4442-4453	acquisition	_
21-11	4454-4460	method	_
21-12	4461-4462	,	_
21-13	4463-4464	a	_
21-14	4465-4471	fourth	_
21-15	4472-4479	dataset	_
21-16	4480-4482	of	_
21-17	4483-4491	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-18	4492-4496	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-19	4497-4510	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-20	4511-4514	was	_
21-21	4515-4523	included	_
21-22	4524-4526	by	_
21-23	4527-4532	means	_
21-24	4533-4535	of	_
21-25	4536-4539	the	_
21-26	4540-4544	open	_
21-27	4545-4558	SchizoConnect	_
21-28	4559-4564	COBRE	_
21-29	4565-4572	dataset	_
21-30	4573-4574	(	_
21-31	4575-4583	SCZcobre	_
21-32	4584-4585	,	_
21-33	4586-4587	n	_
21-34	4588-4589	=	_
21-35	4590-4595	65/75	_
21-36	4596-4597	)	_
21-37	4598-4599	.	_

22-1	4600-4608	Primates	_
22-2	4609-4612	and	_
22-3	4613-4618	human	_
22-4	4619-4626	dataset	_
22-5	4627-4629	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-6	4630-4633	and	_
22-7	4634-4637	DWI	_
22-8	4638-4642	from	_
22-9	4643-4645	22	_
22-10	4646-4651	adult	_
22-11	4652-4663	chimpanzees	_
22-12	4664-4665	(	_
22-13	4666-4669	Pan	_
22-14	4670-4681	troglodytes	_
22-15	4682-4683	,	_
22-16	4684-4688	29.4	_
22-17	4689-4690	±	_
22-18	4691-4695	12.8	_
22-19	4696-4701	years	_
22-20	4702-4703	)	_
22-21	4704-4707	and	_
22-22	4708-4710	58	_
22-23	4711-4716	adult	_
22-24	4717-4728	age-matched	_
22-25	4729-4734	human	_
22-26	4735-4743	subjects	_
22-27	4744-4748	were	_
22-28	4749-4757	included	_
22-29	4758-4759	(	_
22-30	4760-4764	Homo	_
22-31	4765-4772	sapiens	_
22-32	4773-4774	,	_
22-33	4775-4779	42.5	_
22-34	4780-4781	±	_
22-35	4782-4785	9.8	_
22-36	4786-4791	years	_
22-37	4792-4793	)	_
22-38	4794-4795	(	_
22-39	4796-4809	Supplementary	_
22-40	4810-4818	material	_
22-41	4819-4820	)	_
22-42	4821-4822	.	_

23-1	4823-4825	No	_
23-2	4826-4829	new	_
23-3	4830-4840	chimpanzee	_
23-4	4841-4844	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-5	4845-4849	data	_
23-6	4850-4854	were	_
23-7	4855-4863	acquired	_
23-8	4864-4867	for	_
23-9	4868-4872	this	_
23-10	4873-4878	study	_
23-11	4879-4880	.	_

24-1	4881-4884	All	_
24-2	4885-4895	chimpanzee	_
24-3	4896-4900	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
24-4	4901-4905	were	_
24-5	4906-4914	obtained	_
24-6	4915-4919	from	_
24-7	4920-4921	a	_
24-8	4922-4926	data	_
24-9	4927-4934	archive	_
24-10	4935-4937	of	_
24-11	4938-4943	scans	_
24-12	4944-4952	obtained	_
24-13	4953-4958	prior	_
24-14	4959-4961	to	_
24-15	4962-4965	the	_
24-16	4966-4970	2015	_
24-17	4971-4985	implementation	_
24-18	4986-4988	of	_
24-19	4989-4991	US	_
24-20	4992-4996	Fish	_
24-21	4997-5000	and	_
24-22	5001-5009	Wildlife	_
24-23	5010-5017	Service	_
24-24	5018-5021	and	_
24-25	5022-5030	National	_
24-26	5031-5041	Institutes	_
24-27	5042-5044	of	_
24-28	5045-5051	Health	_
24-29	5052-5063	regulations	_
24-30	5064-5073	governing	_
24-31	5074-5082	research	_
24-32	5083-5087	with	_
24-33	5088-5099	chimpanzees	_
24-34	5100-5101	,	_
24-35	5102-5106	with	_
24-36	5107-5110	all	_
24-37	5111-5121	chimpanzee	_
24-38	5122-5127	scans	_
24-39	5128-5137	completed	_
24-40	5138-5140	by	_
24-41	5141-5144	the	_
24-42	5145-5148	end	_
24-43	5149-5151	of	_
24-44	5152-5156	2012	_
24-45	5157-5158	.	_

25-1	5159-5163	Data	_
25-2	5164-5167	are	_
25-3	5168-5176	archived	_
25-4	5177-5179	in	_
25-5	5180-5183	the	_
25-6	5184-5192	National	_
25-7	5193-5203	Chimpanzee	_
25-8	5204-5209	Brain	_
25-9	5210-5218	Resource	_
25-10	5219-5220	(	_
25-11	5221-5226	https	_
25-12	5227-5228	:	_
25-13	5229-5254	//www.chimpanzeebrain.org	_
25-14	5255-5256	)	_
25-15	5257-5258	.	_

26-1	5259-5261	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-2	5262-5265	and	_
26-3	5266-5269	DWI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImagingProtocol
26-4	5270-5274	data	_
26-5	5275-5277	of	_
26-6	5278-5283	eight	_
26-7	5284-5290	rhesus	_
26-8	5291-5299	macaques	_
26-9	5300-5301	(	_
26-10	5302-5308	Macaca	_
26-11	5309-5316	mulatta	_
26-12	5317-5318	,	_
26-13	5319-5321	14	_
26-14	5322-5323	±	_
26-15	5324-5327	6.7	_
26-16	5328-5333	years	_
26-17	5334-5335	)	_
26-18	5336-5340	were	_
26-19	5341-5349	included	_
26-20	5350-5352	as	_
26-21	5353-5355	an	_
26-22	5356-5364	outgroup	_
26-23	5365-5366	.	_

27-1	5367-5370	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-2	5371-5375	data	_
27-3	5376-5380	were	_
27-4	5381-5389	acquired	_
27-5	5390-5392	on	_
27-6	5393-5400	Siemens	_
27-7	5401-5402	3	_
27-8	5403-5404	T	_
27-9	5405-5409	Trio	_
27-10	5410-5413	Tim	_
27-11	5414-5422	Scanners	_
27-12	5423-5426	and	_
27-13	5427-5435	included	_
27-14	5436-5439	the	_
27-15	5440-5451	acquisition	_
27-16	5452-5454	of	_
27-17	5455-5456	a	_
27-18	5457-5467	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-19	5468-5470	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-20	5471-5475	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-21	5476-5479	and	_
27-22	5480-5481	a	_
27-23	5482-5491	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-24	5492-5495	MRI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-25	5496-5500	scan	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-26	5501-5502	.	_

28-1	5503-5513	Macroscale	_
28-2	5514-5532	diffusion-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
28-3	5533-5540	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
28-4	5541-5551	connectome	_
28-5	5552-5564	construction	_
28-6	5565-5568	For	_
28-7	5569-5573	each	_
28-8	5574-5581	subject	_
28-9	5582-5583	,	_
28-10	5584-5587	the	_
28-11	5588-5590	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-12	5591-5596	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-13	5597-5600	was	_
28-14	5601-5610	processed	_
28-15	5611-5616	using	_
28-16	5617-5627	FreeSurfer	_
28-17	5628-5629	,	_
28-18	5630-5638	followed	_
28-19	5639-5641	by	_
28-20	5642-5654	parcellation	_
28-21	5655-5657	of	_
28-22	5658-5661	the	_
28-23	5662-5668	cortex	_
28-24	5669-5674	using	_
28-25	5675-5676	a	_
28-26	5677-5685	114-area	_
28-27	5686-5697	subdivision	_
28-28	5698-5700	of	_
28-29	5701-5704	the	_
28-30	5705-5721	Desikan-Killiany	_
28-31	5722-5727	atlas	_
28-32	5728-5729	(	_
28-33	5730-5736	DK-114	_
28-34	5737-5738	)	_
28-35	5739-5741	of	_
28-36	5742-5750	cortical	_
28-37	5751-5761	structures	_
28-38	5762-5763	(	_
28-39	5764-5777	Supplementary	_
28-40	5778-5786	material	_
28-41	5787-5788	)	_
28-42	5789-5790	.	_

29-1	5791-5804	Deterministic	_
29-2	5805-5810	fibre	_
29-3	5811-5819	tracking	_
29-4	5820-5823	was	_
29-5	5824-5828	used	_
29-6	5829-5831	to	_
29-7	5832-5843	reconstruct	_
29-8	5844-5860	cortico-cortical	_
29-9	5861-5872	connections	_
29-10	5873-5874	,	_
29-11	5875-5879	with	_
29-12	5880-5883	the	_
29-13	5884-5900	cortico-cortical	_
29-14	5901-5913	connectivity	_
29-15	5914-5920	matrix	_
29-16	5921-5934	reconstructed	_
29-17	5935-5937	by	_
29-18	5938-5949	determining	_
29-19	5950-5953	for	_
29-20	5954-5958	each	_
29-21	5959-5963	pair	_
29-22	5964-5966	of	_
29-23	5967-5975	cortical	_
29-24	5976-5983	regions	_
29-25	5984-5991	whether	_
29-26	5992-5995	the	_
29-27	5996-5999	two	_
29-28	6000-6007	regions	_
29-29	6008-6012	were	_
29-30	6013-6027	interconnected	_
29-31	6028-6030	by	_
29-32	6031-6034	DWI	_
29-33	6035-6046	streamlines	_
29-34	6047-6048	[	_
29-35	6049-6052	see	_
29-36	6053-6066	Supplementary	_
29-37	6067-6075	material	_
29-38	6076-6079	for	_
29-39	6080-6087	details	_
29-40	6088-6090	of	_
29-41	6091-6104	preprocessing	_
29-42	6105-6108	and	_
29-43	6109-6114	fibre	_
29-44	6115-6123	tracking	_
29-45	6124-6125	,	_
29-46	6126-6135	including	_
29-47	6136-6146	robustness	_
29-48	6147-6155	analyses	_
29-49	6156-6166	validating	_
29-50	6167-6174	effects	_
29-51	6175-6177	of	_
29-52	6178-6186	movement	_
29-53	6187-6188	,	_
29-54	6189-6204	group-consensus	_
29-55	6205-6212	masking	_
29-56	6213-6214	,	_
29-57	6215-6220	fibre	_
29-58	6221-6233	thresholding	_
29-59	6234-6235	,	_
29-60	6236-6241	fibre	_
29-61	6242-6248	length	_
29-62	6249-6252	and	_
29-63	6253-6263	validation	_
29-64	6264-6266	by	_
29-65	6267-6272	means	_
29-66	6273-6275	of	_
29-67	6276-6279	the	_
29-68	6280-6295	high-resolution	_
29-69	6296-6300	data	_
29-70	6301-6305	from	_
29-71	6306-6309	the	_
29-72	6310-6315	Human	_
29-73	6316-6326	Connectome	_
29-74	6327-6334	Project	_
29-75	6335-6336	]	_
29-76	6337-6338	.	_

30-1	6339-6341	We	_
30-2	6342-6346	used	_
30-3	6347-6357	fractional	_
30-4	6358-6368	anisotropy	_
30-5	6369-6371	as	_
30-6	6372-6373	a	_
30-7	6374-6380	metric	_
30-8	6381-6383	of	_
30-9	6384-6396	connectivity	_
30-10	6397-6405	strength	_
30-11	6406-6408	of	_
30-12	6409-6422	reconstructed	_
30-13	6423-6434	connections	_
30-14	6435-6436	,	_
30-15	6437-6438	a	_
30-16	6439-6445	metric	_
30-17	6446-6451	often	_
30-18	6452-6461	suggested	_
30-19	6462-6464	to	_
30-20	6465-6471	relate	_
30-21	6472-6474	to	_
30-22	6475-6480	tract	_
30-23	6481-6490	integrity	_
30-24	6491-6494	and	_
30-25	6495-6506	myelination	_
30-26	6507-6513	levels	_
30-27	6514-6517	and	_
30-28	6518-6523	often	_
30-29	6524-6528	used	_
30-30	6529-6531	to	_
30-31	6532-6539	examine	_
30-32	6540-6552	case-control	_
30-33	6553-6564	differences	_
30-34	6565-6567	in	_
30-35	6568-6580	connectivity	_
30-36	6581-6589	strength	_
30-37	6590-6591	.	_

31-1	6592-6602	Fractional	_
31-2	6603-6613	anisotropy	_
31-3	6614-6621	weights	_
31-4	6622-6626	were	_
31-5	6627-6636	resampled	_
31-6	6637-6639	in	_
31-7	6640-6643	the	_
31-8	6644-6655	comparative	_
31-9	6656-6663	dataset	_
31-10	6664-6666	to	_
31-11	6667-6668	a	_
31-12	6669-6677	Gaussian	_
31-13	6678-6690	distribution	_
31-14	6691-6692	(	_
31-15	6693-6697	mean	_
31-16	6698-6699	=	_
31-17	6700-6703	0.5	_
31-18	6704-6705	,	_
31-19	6706-6714	standard	_
31-20	6715-6724	deviation	_
31-21	6725-6726	=	_
31-22	6727-6731	0.15	_
31-23	6732-6733	)	_
31-24	6734-6736	to	_
31-25	6737-6742	allow	_
31-26	6743-6746	for	_
31-27	6747-6760	cross-species	_
31-28	6761-6771	comparison	_
31-29	6772-6775	and	_
31-30	6776-6778	to	_
31-31	6779-6783	rule	_
31-32	6784-6787	out	_
31-33	6788-6794	global	_
31-34	6795-6806	differences	_
31-35	6807-6808	(	_
31-36	6809-6822	Supplementary	_
31-37	6823-6831	material	_
31-38	6832-6833	)	_
31-39	6834-6835	.	_

32-1	6836-6844	Analysis	_
32-2	6845-6847	of	_
32-3	6848-6854	number	_
32-4	6855-6857	of	_
32-5	6858-6869	streamlines	_
32-6	6870-6873	and	_
32-7	6874-6891	volume-normalized	_
32-8	6892-6902	streamline	_
32-9	6903-6910	density	_
32-10	6911-6913	as	_
32-11	6914-6916	an	_
32-12	6917-6928	alternative	_
32-13	6929-6935	metric	_
32-14	6936-6938	of	_
32-15	6939-6951	connectivity	_
32-16	6952-6960	strength	_
32-17	6961-6964	did	_
32-18	6965-6968	not	_
32-19	6969-6973	show	_
32-20	6974-6981	overlap	_
32-21	6982-6986	with	_
32-22	6987-6994	patient	_
32-23	6995-7002	effects	_
32-24	7003-7004	,	_
32-25	7005-7007	so	_
32-26	7008-7010	we	_
32-27	7011-7018	further	_
32-28	7019-7026	focused	_
32-29	7027-7029	on	_
32-30	7030-7040	fractional	_
32-31	7041-7051	anisotropy	_
32-32	7052-7054	in	_
32-33	7055-7058	our	_
32-34	7059-7067	analysis	_
32-35	7068-7069	.	_

33-1	7070-7075	Brain	_
33-2	7076-7091	dysconnectivity	_
33-3	7092-7105	Schizophrenia	_
33-4	7106-7111	brain	_
33-5	7112-7127	dysconnectivity	_
33-6	7128-7131	was	_
33-7	7132-7140	assessed	_
33-8	7141-7143	by	_
33-9	7144-7154	performing	_
33-10	7155-7163	edgewise	_
33-11	7164-7174	comparison	_
33-12	7175-7177	of	_
33-13	7178-7181	the	_
33-14	7182-7195	reconstructed	_
33-15	7196-7207	connections	_
33-16	7208-7215	between	_
33-17	7216-7223	patient	_
33-18	7224-7227	and	_
33-19	7228-7235	control	_
33-20	7236-7246	connectome	_
33-21	7247-7251	maps	_
33-22	7252-7253	.	_

34-1	7254-7267	Between-group	_
34-2	7268-7278	difference	_
34-3	7279-7282	was	_
34-4	7283-7288	taken	_
34-5	7289-7291	as	_
34-6	7292-7295	the	_
34-7	7296-7307	t-statistic	_
34-8	7308-7310	of	_
34-9	7311-7312	a	_
34-10	7313-7323	two-sample	_
34-11	7324-7330	t-test	_
34-12	7331-7341	comparison	_
34-13	7342-7349	between	_
34-14	7350-7358	edgewise	_
34-15	7359-7369	fractional	_
34-16	7370-7380	anisotropy	_
34-17	7381-7387	values	_
34-18	7388-7390	of	_
34-19	7391-7394	the	_
34-20	7395-7403	patients	_
34-21	7404-7407	and	_
34-22	7408-7415	control	_
34-23	7416-7424	subjects	_
34-24	7425-7426	,	_
34-25	7427-7431	with	_
34-26	7432-7438	higher	_
34-27	7439-7451	t-statistics	_
34-28	7452-7462	indicating	_
34-29	7463-7470	greater	_
34-30	7471-7486	dysconnectivity	_
34-31	7487-7489	in	_
34-32	7490-7503	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-33	7504-7512	patients	_
34-34	7513-7514	(	_
34-35	7515-7528	Supplementary	_
34-36	7529-7537	material	_
34-37	7538-7539	)	_
34-38	7540-7541	.	_

35-1	7542-7557	Dysconnectivity	_
35-2	7558-7562	maps	_
35-3	7563-7566	for	_
35-4	7567-7570	the	_
35-5	7571-7576	other	_
35-6	7577-7585	disorder	_
35-7	7586-7594	datasets	_
35-8	7595-7599	were	_
35-9	7600-7607	derived	_
35-10	7608-7613	using	_
35-11	7614-7617	the	_
35-12	7618-7622	same	_
35-13	7623-7632	procedure	_
35-14	7633-7634	.	_

36-1	7635-7640	Human	_
36-2	7641-7654	modifications	_
36-3	7655-7657	to	_
36-4	7658-7663	brain	_
36-5	7664-7676	connectivity	_
36-6	7677-7691	Human-specific	_
36-7	7692-7703	connections	_
36-8	7704-7718	Human-specific	_
36-9	7719-7730	connections	_
36-10	7731-7735	were	_
36-11	7736-7744	selected	_
36-12	7745-7747	as	_
36-13	7748-7751	the	_
36-14	7752-7755	set	_
36-15	7756-7758	of	_
36-16	7759-7770	connections	_
36-17	7771-7775	that	_
36-18	7776-7780	were	_
36-19	7781-7789	observed	_
36-20	7790-7792	in	_
36-21	7793-7796	≥60	_
36-22	7797-7798	%	_
36-23	7799-7801	of	_
36-24	7802-7805	the	_
36-25	7806-7811	human	_
36-26	7812-7820	subjects	_
36-27	7821-7824	and	_
36-28	7825-7827	in	_
36-29	7828-7832	none	_
36-30	7833-7835	of	_
36-31	7836-7839	the	_
36-32	7840-7850	chimpanzee	_
36-33	7851-7861	connectome	_
36-34	7862-7866	maps	_
36-35	7867-7868	(	_
36-36	7869-7872	i.e	_
36-37	7873-7874	.	_

37-1	7875-7876	0	_
37-2	7877-7878	%	_
37-3	7879-7881	of	_
37-4	7882-7885	the	_
37-5	7886-7896	chimpanzee	_
37-6	7897-7905	subjects	_
37-7	7906-7907	)	_
37-8	7908-7909	.	_

38-1	7910-7912	We	_
38-2	7913-7917	used	_
38-3	7918-7922	this	_
38-4	7923-7929	strict	_
38-5	7930-7940	prevalence	_
38-6	7941-7946	group	_
38-7	7947-7956	threshold	_
38-8	7957-7959	of	_
38-9	7960-7962	60	_
38-10	7963-7964	%	_
38-11	7965-7966	(	_
38-12	7967-7972	human	_
38-13	7973-7974	)	_
38-14	7975-7978	and	_
38-15	7979-7988	exclusion	_
38-16	7989-7998	threshold	_
38-17	7999-8001	of	_
38-18	8002-8003	0	_
38-19	8004-8005	%	_
38-20	8006-8007	(	_
38-21	8008-8018	chimpanzee	_
38-22	8019-8020	)	_
38-23	8021-8023	to	_
38-24	8024-8030	reduce	_
38-25	8031-8034	the	_
38-26	8035-8044	inclusion	_
38-27	8045-8047	of	_
38-28	8048-8062	false-positive	_
38-29	8063-8078	reconstructions	_
38-30	8079-8081	at	_
38-31	8082-8085	the	_
38-32	8086-8091	group	_
38-33	8092-8097	level	_
38-34	8098-8101	and	_
38-35	8102-8104	to	_
38-36	8105-8112	include	_
38-37	8113-8114	a	_
38-38	8115-8127	conservative	_
38-39	8128-8138	definition	_
38-40	8139-8141	of	_
38-41	8142-8156	human-specific	_
38-42	8157-8163	tracts	_
38-43	8164-8165	(	_
38-44	8166-8179	Supplementary	_
38-45	8180-8188	material	_
38-46	8189-8190	)	_
38-47	8191-8192	.	_

39-1	8193-8195	We	_
39-2	8196-8199	use	_
39-3	8200-8203	the	_
39-4	8204-8208	term	_
39-5	8209-8210	‘	_
39-6	8211-8225	human-specific	_
39-7	8226-8227	’	_
39-8	8228-8231	for	_
39-9	8232-8237	these	_
39-10	8238-8249	connections	_
39-11	8250-8251	,	_
39-12	8252-8255	but	_
39-13	8256-8258	we	_
39-14	8259-8263	note	_
39-15	8264-8268	that	_
39-16	8269-8273	with	_
39-17	8274-8278	this	_
39-18	8279-8283	term	_
39-19	8284-8285	,	_
39-20	8286-8288	we	_
39-21	8289-8292	are	_
39-22	8293-8296	not	_
39-23	8297-8305	directly	_
39-24	8306-8314	implying	_
39-25	8315-8319	that	_
39-26	8320-8326	humans	_
39-27	8327-8330	are	_
39-28	8331-8342	necessarily	_
39-29	8343-8346	the	_
39-30	8347-8351	only	_
39-31	8352-8359	primate	_
39-32	8360-8367	species	_
39-33	8368-8370	to	_
39-34	8371-8378	possess	_
39-35	8379-8384	these	_
39-36	8385-8396	connections	_
39-37	8397-8398	.	_

40-1	8399-8422	Human-chimpanzee-shared	_
40-2	8423-8434	connections	_
40-3	8435-8439	were	_
40-4	8440-8448	selected	_
40-5	8449-8451	as	_
40-6	8452-8455	the	_
40-7	8456-8462	subset	_
40-8	8463-8465	of	_
40-9	8466-8482	cortico-cortical	_
40-10	8483-8494	connections	_
40-11	8495-8499	that	_
40-12	8500-8504	were	_
40-13	8505-8517	consistently	_
40-14	8518-8526	observed	_
40-15	8527-8529	in	_
40-16	8530-8534	both	_
40-17	8535-8542	species	_
40-18	8543-8544	(	_
40-19	8545-8548	≥60	_
40-20	8549-8550	%	_
40-21	8551-8553	of	_
40-22	8554-8560	humans	_
40-23	8561-8564	and	_
40-24	8565-8568	≥60	_
40-25	8569-8570	%	_
40-26	8571-8573	of	_
40-27	8574-8585	chimpanzees	_
40-28	8586-8587	)	_
40-29	8588-8589	.	_

41-1	8590-8597	Results	_
41-2	8598-8602	were	_
41-3	8603-8611	verified	_
41-4	8612-8617	using	_
41-5	8618-8623	other	_
41-6	8624-8633	threshold	_
41-7	8634-8642	settings	_
41-8	8643-8644	(	_
41-9	8645-8658	Supplementary	_
41-10	8659-8667	material	_
41-11	8668-8669	)	_
41-12	8670-8671	.	_

42-1	8672-8675	For	_
42-2	8676-8679	the	_
42-3	8680-8685	class	_
42-4	8686-8688	of	_
42-5	8689-8695	shared	_
42-6	8696-8707	connections	_
42-7	8708-8709	,	_
42-8	8710-8713	the	_
42-9	8714-8719	level	_
42-10	8720-8722	of	_
42-11	8723-8730	species	_
42-12	8731-8741	difference	_
42-13	8742-8745	was	_
42-14	8746-8754	computed	_
42-15	8755-8757	as	_
42-16	8758-8761	the	_
42-17	8762-8775	between-group	_
42-18	8776-8787	t-statistic	_
42-19	8788-8795	between	_
42-20	8796-8799	the	_
42-21	8800-8810	normalized	_
42-22	8811-8821	fractional	_
42-23	8822-8832	anisotropy	_
42-24	8833-8839	values	_
42-25	8840-8842	of	_
42-26	8843-8846	the	_
42-27	8847-8858	constructed	_
42-28	8859-8870	connections	_
42-29	8871-8873	of	_
42-30	8874-8877	the	_
42-31	8878-8883	group	_
42-32	8884-8886	of	_
42-33	8887-8898	chimpanzees	_
42-34	8899-8902	and	_
42-35	8903-8906	the	_
42-36	8907-8912	group	_
42-37	8913-8915	of	_
42-38	8916-8922	humans	_
42-39	8923-8924	(	_
42-40	8925-8938	Supplementary	_
42-41	8939-8947	material	_
42-42	8948-8949	)	_
42-43	8950-8951	.	_

43-1	8952-8962	Validation	_
43-2	8963-8979	chimpanzee-human	_
43-3	8980-8990	homologous	_
43-4	8991-8995	BB38	_
43-5	8996-8998	We	_
43-6	8999-9004	opted	_
43-7	9005-9008	for	_
43-8	9009-9012	the	_
43-9	9013-9016	use	_
43-10	9017-9019	of	_
43-11	9020-9023	the	_
43-12	9024-9040	Desikan-Killiany	_
43-13	9041-9046	brain	_
43-14	9047-9052	atlas	_
43-15	9053-9055	to	_
43-16	9056-9058	be	_
43-17	9059-9061	in	_
43-18	9062-9066	line	_
43-19	9067-9071	with	_
43-20	9072-9080	previous	_
43-21	9081-9091	connectome	_
43-22	9092-9099	studies	_
43-23	9100-9102	of	_
43-24	9103-9108	brain	_
43-25	9109-9118	disorders	_
43-26	9119-9120	,	_
43-27	9121-9130	including	_
43-28	9131-9136	those	_
43-29	9137-9139	in	_
43-30	9140-9153	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
43-31	9154-9155	.	_

44-1	9156-9163	However	_
44-2	9164-9165	,	_
44-3	9166-9169	the	_
44-4	9170-9186	Desikan-Killiany	_
44-5	9187-9192	atlas	_
44-6	9193-9195	is	_
44-7	9196-9204	designed	_
44-8	9205-9207	to	_
44-9	9208-9211	map	_
44-10	9212-9215	the	_
44-11	9216-9220	gyri	_
44-12	9221-9224	and	_
44-13	9225-9230	sulci	_
44-14	9231-9241	patterning	_
44-15	9242-9244	of	_
44-16	9245-9248	the	_
44-17	9249-9254	human	_
44-18	9255-9263	cortical	_
44-19	9264-9270	mantle	_
44-20	9271-9274	and	_
44-21	9275-9276	a	_
44-22	9277-9289	disadvantage	_
44-23	9290-9292	of	_
44-24	9293-9298	using	_
44-25	9299-9303	this	_
44-26	9304-9309	atlas	_
44-27	9310-9312	in	_
44-28	9313-9314	a	_
44-29	9315-9328	human-primate	_
44-30	9329-9341	neuroimaging	_
44-31	9342-9347	study	_
44-32	9348-9350	is	_
44-33	9351-9355	thus	_
44-34	9356-9360	that	_
44-35	9361-9363	it	_
44-36	9364-9368	does	_
44-37	9369-9372	not	_
44-38	9373-9384	necessarily	_
44-39	9385-9393	describe	_
44-40	9394-9404	homologous	_
44-41	9405-9422	cytoarchitectonic	_
44-42	9423-9430	regions	_
44-43	9431-9437	across	_
44-44	9438-9441	the	_
44-45	9442-9445	two	_
44-46	9446-9453	species	_
44-47	9454-9455	.	_

45-1	9456-9458	We	_
45-2	9459-9468	therefore	_
45-3	9469-9478	validated	_
45-4	9479-9482	our	_
45-5	9483-9491	findings	_
45-6	9492-9497	using	_
45-7	9498-9502	data	_
45-8	9503-9507	from	_
45-9	9508-9511	the	_
45-10	9512-9515	von	_
45-11	9516-9521	Bonin	_
45-12	9522-9525	and	_
45-13	9526-9532	Bailey	_
45-14	9533-9534	(	_
45-15	9535-9539	BB38	_
45-16	9540-9541	)	_
45-17	9542-9550	cortical	_
45-18	9551-9556	atlas	_
45-19	9557-9565	designed	_
45-20	9566-9568	to	_
45-21	9569-9572	map	_
45-22	9573-9583	homologous	_
45-23	9584-9591	regions	_
45-24	9592-9598	across	_
45-25	9599-9605	humans	_
45-26	9606-9609	and	_
45-27	9610-9621	chimpanzees	_
45-28	9622-9623	.	_

46-1	9624-9628	This	_
46-2	9629-9634	atlas	_
46-3	9635-9644	describes	_
46-4	9645-9647	38	_
46-5	9648-9658	homologous	_
46-6	9659-9667	cortical	_
46-7	9668-9673	areas	_
46-8	9674-9677	per	_
46-9	9678-9688	hemisphere	_
46-10	9689-9695	across	_
46-11	9696-9702	humans	_
46-12	9703-9706	and	_
46-13	9707-9718	chimpanzees	_
46-14	9719-9724	based	_
46-15	9725-9727	on	_
46-16	9728-9745	cytoarchitectonic	_
46-17	9746-9756	similarity	_
46-18	9757-9759	of	_
46-19	9760-9768	cortical	_
46-20	9769-9774	areas	_
46-21	9775-9776	(	_
46-22	9777-9790	Supplementary	_
46-23	9791-9799	material	_
46-24	9800-9803	and	_
46-25	9804-9817	Supplementary	_
46-26	9818-9821	Fig	_
46-27	9822-9823	.	_

47-1	9824-9825	3	_
47-2	9826-9827	)	_
47-3	9828-9829	.	_

48-1	9830-9834	Data	_
48-2	9835-9847	availability	_
48-3	9848-9858	Chimpanzee	_
48-4	9859-9863	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
48-5	9864-9867	are	_
48-6	9868-9876	archived	_
48-7	9877-9879	in	_
48-8	9880-9883	the	_
48-9	9884-9892	National	_
48-10	9893-9903	Chimpanzee	_
48-11	9904-9909	Brain	_
48-12	9910-9918	Resource	_
48-13	9919-9920	(	_
48-14	9921-9925	data	_
48-15	9926-9935	available	_
48-16	9936-9938	at	_
48-17	9939-9944	https	_
48-18	9945-9946	:	_
48-19	9947-9972	//www.chimpanzeebrain.org	_
48-20	9973-9974	)	_
48-21	9975-9976	.	_

49-1	9977-9984	Species	_
49-2	9985-9997	connectivity	_
49-3	9998-10006	matrices	_
49-4	10007-10010	are	_
49-5	10011-10020	available	_
49-6	10021-10023	at	_
49-7	10024-10027	the	_
49-8	10028-10031	USC	_
49-9	10032-10042	Multimodal	_
49-10	10043-10055	Connectivity	_
49-11	10056-10064	Database	_
49-12	10065-10066	(	_
49-13	10067-10071	UMCD	_
49-14	10072-10073	)	_
49-15	10074-10075	,	_
49-16	10076-10080	http	_
49-17	10081-10082	:	_
49-18	10083-10116	//umcd.humanconnectomeproject.org	_
49-19	10117-10118	(	_
49-20	10119-10121	ID	_
49-21	10122-10126	3036	_
49-22	10127-10128	,	_
49-23	10129-10133	3037	_
49-24	10134-10135	,	_
49-25	10136-10140	3038	_
49-26	10141-10142	,	_
49-27	10143-10147	3039	_
49-28	10148-10149	)	_
49-29	10150-10151	.	_

50-1	10152-10159	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
50-2	10160-10165	human	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
50-3	10166-10176	connectome	_
50-4	10177-10181	data	_
50-5	10182-10186	from	_
50-6	10187-10190	the	_
50-7	10191-10196	Human	_
50-8	10197-10207	Connectome	_
50-9	10208-10215	Project	_
50-10	10216-10219	are	_
50-11	10220-10229	available	_
50-12	10230-10237	through	_
50-13	10238-10241	the	_
50-14	10242-10247	Human	_
50-15	10248-10258	Connectome	_
50-16	10259-10266	Project	_
50-17	10267-10271	data	_
50-18	10272-10278	portal	_
50-19	10279-10280	(	_
50-20	10281-10286	https	_
50-21	10287-10288	:	_
50-22	10289-10314	//www.humanconnectome.org	_
50-23	10315-10316	)	_
50-24	10317-10318	.	_

51-1	10319-10326	Patient	_
51-2	10327-10342	dysconnectivity	_
51-3	10343-10347	maps	_
51-4	10348-10351	are	_
51-5	10352-10361	available	_
51-6	10362-10364	on	_
51-7	10365-10375	reasonable	_
51-8	10376-10383	request	_
51-9	10384-10386	to	_
51-10	10387-10390	the	_
51-11	10391-10404	corresponding	_
51-12	10405-10411	author	_
51-13	10412-10413	.	_

